Revel Pharmaceuticals

San Francisco, CA · Founded 2019 · Privately Held (backing)

Developer of therapeutic enzymes designed for degrading molecular damage associated with aging. Revel Pharmaceuticals is based in San Francisco, CA and was founded in 2019. It was valued at $15 million at its early-stage round in Mar 2022, the last priced event on record. It has raised $14.7 million across 3 recorded rounds; the latest was a $5.8 million early-stage round in Feb 2022.

PMV mark · valuation
$15.0M
Oct 2026
Priced at
its early-stage round
Mar 2022
Total raised
$14.7M
Last round
Early Stage VC
Feb 2022

Who backs Revel Pharmaceuticals?

9 investors
InvestorType
GaingelsVenture capital
Formic Ventures—
Starbloom CapitalFamily office
Kizoo Technology Capital—
Lifespan Extension Advocacy Foundation—
LongGame—
MBC BioLabs—
Michael Antonov—
U.S. Department of Health and Human Services—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Revel Pharmaceuticals investors

9 investors are on record for Revel Pharmaceuticals, including Gaingels, Formic Ventures, Starbloom Capital and Kizoo Technology Capital. The early-stage round in Feb 2022 drew 3 investors.

Free account
More of Revel Pharmaceuticals with a free account
  • ·Watch Revel Pharmaceuticals: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 9 firms already write checks for companies like Revel Pharmaceuticals. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View